Skip to Content

What type of drug is Emgality?

Medically reviewed by Last updated on Nov 7, 2018.

Official Answer


Emgality (galcanezumab-gnlm) is a calcitonin gene-related peptide (CGRP) antagonist.

It is the third drug approved in this new class for migraine prevention in adults. When CGRP binds to its receptor, a cascade of events such as vasodilation and protein leakage begin that results in inflammation and pain associated with migraine.

Dosing for Emgality is 120 mg given once monthly by subcutaneous (under the skin) injection after an initial, one-time, 240 mg loading dose.

Emgality from Eli Lilly joins the previously approved CGRP antagonists Ajovy (fremanezumab-vfrm) from Teva Pharmaceutical and Aimovig (erenumab-aooe) from Amgen.

How do calcitonin gene-related peptide (CGRP) antagonists work?

  • Emgality and Ajovy work similarly: they bind to the CGRP ligand and block its binding to the receptor to help prevent migraine pain.
  • Aimovig actually selectively binds to the CGRP receptor (not the ligand) to block CGRP activation, thereby preventing migraine pain.

Related Drug Information